Diabetes drug metformin may stop precancerous blood condition from turning into cancer

NCT ID NCT04850846

First seen Sep 30, 2025 · Last updated Apr 24, 2026 · Updated 22 times

Summary

This study tests whether metformin, a widely used diabetes medicine, can prevent the progression of two precancerous blood conditions (MGUS and smoldering multiple myeloma) into active multiple myeloma. About 60 participants will receive either metformin or a placebo pill for a period of time. Researchers will track changes in protein levels and other markers to see if metformin can slow or stop the disease from advancing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

  • DF/ BWCC in Clinical Affiliation with South Shore Hospital

    Weymouth, Massachusetts, 02190, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Dana-Farber at Brighton

    Brighton, Massachusetts, 02135, United States

  • Dana-Farber at Merrimack Valley

    Methuen, Massachusetts, 01844, United States

  • Dana-Farber at Milford

    Milford, Massachusetts, 01757, United States

  • Dana-Farber at NHOH

    Londonderry, New Hampshire, 35053, United States

Conditions

Explore the condition pages connected to this study.